Kyverna Therapeutics (KYTX) Current Leases (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Current Leases came in at $1.8 million in Q1 2026, up 247.93% YoY from $507000.0 in Q1 2025, and down 51.83% on a QoQ basis from $3.7 million in Q4 2025.
Kyverna Therapeutics (KYTX) Current Leases (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Current Leases data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Current Leases rose 247.93% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 247.93% YoY) and the FY2025 annual result came in at $3.7 million, up 15.85% from the prior year.
- Current Leases slipped to $1.8 million in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $3.7 million in Q4 2025 to a low of $190000.0 in Q3 2025.
- A 4-year average of $1.4 million and a median of $991000.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2025 — Current Leases plunged 79.59% — and 2026, when it jumped 247.93%.
- Tracing KYTX's Current Leases over 4 years: stood at $2.0 million in 2023, then surged by 60.95% to $3.2 million in 2024, then rose by 15.85% to $3.7 million in 2025, then plunged by 51.83% to $1.8 million in 2026.
- The last three Current Leases figures came in at $1.8 million (Q1 2026), $3.7 million (Q4 2025), and $190000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 3.66 Mn |
| Sep 30, 2025 | 190,000.00 |
| Jun 30, 2025 | 292,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 931,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 979,000.00 |
| Dec 31, 2023 | 1.96 Mn |